Equities researchers at StockNews.com assumed coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) in a research report issued to clients and investors on Tuesday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Stock Down 3.2 %
Shares of TTNP stock opened at $5.13 on Tuesday. The stock has a 50-day moving average of $5.83 and a 200-day moving average of $6.25. Titan Pharmaceuticals has a one year low of $4.24 and a one year high of $14.80.
Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) last posted its earnings results on Thursday, August 15th. The specialty pharmaceutical company reported ($2.29) earnings per share for the quarter.
About Titan Pharmaceuticals
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
Featured Articles
- Five stocks we like better than Titan Pharmaceuticals
- The Role Economic Reports Play in a Successful Investment Strategy
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- What Does a Gap Up Mean in Stocks? How to Play the Gap
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Stock Sentiment Analysis: How it Works
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
